Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cellular Injury V: Apoptosis and Autophagy

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Important factors in the choice of dialysis modality among Japanese patients initiating peritoneal dialysis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026

Same author

Time-Course Changes in Biomarker Levels Observed in Effluent of Patients Administered Bicarbonate/Lactate-Buffered Neutral-pH Peritoneal Dialysis Fluid.

Blood purification·2026

Same author

Minocycline infusion sclerotherapy for infected hepatic cysts in a patient with autosomal dominant polycystic kidney disease: a case report and literature review.

CEN case reports·2026

Same author

Peritoneal Lavage With Low GDP Neutral pH PD Solution Reduces Mortality and Severity in a Lethal Peritonitis Model.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·2025

Same author

The epidemiology of encapsulating peritoneal sclerosis in an era of biocompatible neutral peritoneal dialysis solution in Japan.

Clinical and experimental nephrology·2025

Same author

Clinical impact of device connections on PD-related peritonitis.

Clinical and experimental nephrology·2025

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Intervention for apoptosis in cardiomyopathy.

Hiroyuki Yaoita¹, Yukio Maruyama

¹First Department of Internal Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, Japan.

Heart Failure Reviews

|December 15, 2007

Summary

Antiapoptotic interventions are crucial for treating cardiomyopathies. Future strategies may involve cardiac stem cells for heart repair and regeneration, offering promising therapeutic potential.

Area of Science:

Cardiology
Molecular Biology
Regenerative Medicine

Background:

Apoptosis is a key factor in cardiomyopathy development.
Antiapoptotic strategies are proposed as effective treatments for cardiomyopathies.

Purpose of the Study:

To review current and future antiapoptotic interventions for cardiomyopathies.
To explore the role of stem cells and regenerative medicine in cardiac repair.

Main Methods:

Review of existing literature on antiapoptotic therapies.
Analysis of pharmacotherapies, non-pharmacotherapies, and regenerative approaches.
Discussion of clinical trials and future therapeutic strategies.

Main Results:

Conventional pharmacotherapy includes "old wine in a new bottle" antiapoptotic measures.

More Related Videos

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

Related Experiment Videos

Last Updated: Jul 9, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

Specific antiapoptotic treatments like caspase inhibitors and anti-TNF-alpha antibody are in early clinical development.

Non-pharmacotherapies and stem cell transplantation show cardioprotective effects partly via antiapoptotic mechanisms.

Conclusions:

Antiapoptotic interventions are vital for managing cardiomyopathies.
Cardiac stem cell therapy holds promise for future cardiac repair and regeneration.
A combination of existing and novel antiapoptotic strategies may advance clinical cardiology.